UA-93693832-1skip to primary navigationskip to content
 

Consortium Partners

Click on the individual company logo below to get more detail on what each company can offer

 

 175 logo astex T               175 logo astrazeneca T                                               

                     175 logo shionogi T

                                                                                                                                                                                                  

Table 1: Areas of interest of individual companies

Consortium Areas of Interest

                                                                                                                                                                                          

A flexible approach to collaboration

The Milner Therapeutics Consortium companies offer a wide range of collaborative opportunities to academic scientists which balance the needs of the company, the individual scientists involved and the project undertaken. These include advising on nascent drug development ideas, sabbaticals where academic scientists can spend time in industry and access to industry resource, equipment, compounds and funding. We aim to develop strong collaborations that play to each partner’s strengths.

The therapeutic areas of interest that Consortium companies have prioritised for collaboration are listed in the table above. More detail is provided in the individual pages for each company. Click on the company logo to see detail for AstraZeneca, Astex, GlaxoSmithKline or Shionogi. All companies are interested generally in technological innovation and new ideas in chemistry, mathematics and engineering that may span therapeutic areas. 

Compound libraries are available

Compound banks from the companies are available for research and access to these is facilitated for scientists at the University of Cambridge, Sanger Institute and Babraham Institute through the Consortium agreement. Compound sets are available to explore disease biology, for preclinical and clinical research and also to reposition drugs that have already been tested in the clinic. 

 or click on the individual company to find out more.